Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03691623
Other study ID # EDP 938-101
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 15, 2018
Est. completion date October 18, 2019

Study information

Verified date August 2019
Source Enanta Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.


Recruitment information / eligibility

Status Completed
Enrollment 179
Est. completion date October 18, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - An informed consent document signed and dated by the subject - Age 18 to 55 years, inclusive - In good health with no history of major medical conditions - A total body weight = 50 kg and Body Mass Index (BMI) = 18 kg/m^2 and = 30kg/m^2 Exclusion Criteria: - Pregnant or nursing females - Acute or chronic medical illness - Abnormal lung function - Positive for human immunodeficiency virus (HIV), active hepatitis A, B or C test - Nose or nasopharynx abnormalities - Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dose of study drug

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EDP-938 Dose 1
Oral suspension for 5 days
EDP-938 Dose 2
Oral suspension for 5 days
Placebo
Oral suspension for 5 days
EDP-938 Dose 3
Oral suspension for 5 days
EDP-938 Dose 4
Oral suspension for 5 days
Placebo
Oral suspension for 5 days

Locations

Country Name City State
United Kingdom hVIVO Services Limited (hVIVO) London

Sponsors (2)

Lead Sponsor Collaborator
Enanta Pharmaceuticals hVIVO Services Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b. Twice daily on Day 2 through Day 11 and once on Day 12
Secondary Area Under the Curve (AUC) of Total Symptom Score Total symptom scores (from the 10-item Diary Card) were used to calculate the AUC. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities:
Runny nose
Stuffy nose
Sneezing
Sore throat
Earache
Malaise (Tiredness)
Cough
Shortness of breath
Headache
Muscle/ joint ache/ stiffness
Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). Data presented is hours x score.
Three times daily on Day 0 to Day 11, once on Day 12
Secondary Peak Total Symptom Score Peak total symptom score was defined as the highest total symptom score between first dose of study drug and Day 12. Values presented are a sum of individual symptom scores, with a potential range of 0 (best) to 30 (worst). Total symptom scores at the time of the first dose of study drug can be before or after dosing.
Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities:
Runny nose
Stuffy nose
Sneezing
Sore throat
Earache
Malaise (Tiredness)
Cough
Shortness of breath
Headache
Muscle/ joint ache/ stiffness
Day 2 to Day 12
Secondary Total Symptom Score Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities. Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst).
Runny nose
Stuffy nose
Sneezing
Sore throat
Earache
Malaise (Tiredness)
Cough
Shortness of breath
Headache
Muscle/ joint ache/ stiffness
Day 2 to Day 9
Secondary Time to Peak Total Symptom Score Time to peak total symptom score was defined as the time in days to the highest total symptom score between first dose of study drug and Day 12. Total symptom scores at the time of the first dose of study drug can be before or after dosing. Day 2 to Day 12
Secondary Time to Resolution From Peak Total Symptom Score Time to resolution from peak total symptom score was defined as the time in days from the highest total symptom score (between first dose of study drug and Day 12) until the start of the first 24-hour symptom-free period (after the highest total symptom score). Total symptom scores at the time of the first dose of study drug can be before or after dosing. Day 2 to Day 12
Secondary Total Weight of Nasal Mucus Produced Measured via weighed paper tissues and reported as a mean total across all study days. Day 2 to Day 12
Secondary Peak Viral Load Peak viral load was defined as the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR. Day 2 to Day 12
Secondary Time to Peak Viral Load Time to peak viral load was defined as the time to the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR. Day 2 to Day 12
Secondary Time to Resolution From Peak Viral Load Time to resolution from peak viral load was defined as the time from peak until first confirmed undetectable assessment between first dose of study drug and Day 12. Measured by by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR). Day 2 to Day 12
Secondary Time to Cessation of Virus Detection Time to cessation of virus detection was measured by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR). Day 2 to Day 12
Secondary Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs) A TEAE was defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, coagulation [if required], cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events. Day 2 to Day 28
Secondary Maximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Time to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Terminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938 Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Terminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (?z) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Volume of Distribution at Steady State (Vss/F) of EDP-938 Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Plasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2 and Day 7; 12 hours post-dose
Secondary Plasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2 and Day 7; 24 hours post-dose
Secondary Area Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595. Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Secondary Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable viral load AUC i.e. a low PK AUC and a high viral load AUC indicated a correlation. Day 2 to Day 18
Secondary Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable TSS AUC, i.e. a low PK AUC and a high TSS AUC indicated a correlation. Day 2 to Day 18
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03698084 - RESCEU: Defining the Burden of RSV Disease
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05587478 - A Study of EDP-323 in Healthy Subjects Phase 1
Recruiting NCT06180993 - Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Suspended NCT03909867 - Emission Patterns of Respiratory Syncytial Virus
Recruiting NCT06259487 - Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis. N/A
Not yet recruiting NCT04144816 - Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
Completed NCT01090557 - Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study N/A
Terminated NCT01475305 - Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV) Phase 1
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03062917 - Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis N/A
Completed NCT03387137 - Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children Phase 1
Completed NCT05070975 - Severity of RSV Infections in Twins
Active, not recruiting NCT04938830 - Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Phase 3
Recruiting NCT05568706 - A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. Phase 2
Completed NCT03755778 - Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects Phase 1
Completed NCT01483911 - ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers Phase 1
Recruiting NCT06170242 - A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model Phase 2
Completed NCT03750383 - Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects Phase 1
Completed NCT05118386 - Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults Phase 1